Drug profile · INN
olezarsen
TRYNGOLZA
olezarsen (TRYNGOLZA) is a apolipoprotein c-iii mrna antisense inhibitor.
EMA: approved Cardiovascular system (C10) C10AX
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — olezarsen
- Class
- Cardiovascular system (C10)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.83
Quick answer
olezarsen (TRYNGOLZA) is a apolipoprotein c-iii mrna antisense inhibitor.
Key facts
INN olezarsen
Brand TRYNGOLZA
Mechanism Apolipoprotein C-III mRNA antisense inhibitor
Target Apolipoprotein C-III mRNA
Therapeutic class Cardiovascular system (C10)
ATC code C10AX
Mechanism of action
Apolipoprotein C-III mRNA antisense inhibitor
Primary target: Apolipoprotein C-III mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is olezarsen?
olezarsen (TRYNGOLZA) is a apolipoprotein c-iii mrna antisense inhibitor.
What is the brand name for olezarsen?
TRYNGOLZA is a marketed brand name for olezarsen. Check FDA Drugs@FDA for the current US label holder and prescribing information.